Community Acquired Pneumonia is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Community Acquired Pneumonia have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Community Acquired Pneumonia compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Community Acquired Pneumonia overview
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Community Acquired Pneumonia, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.